-$2.71 EPS Expected for Esperion Therapeutics Inc (NASDAQ:ESPR) This Quarter

Wall Street analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce earnings per share (EPS) of ($2.71) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.80) and the highest estimate coming in at ($2.61). Esperion Therapeutics reported earnings per share of ($2.24) during the same quarter last year, which suggests a negative year-over-year growth rate of 21%. The business is expected to issue its next quarterly earnings results on Thursday, February 27th.

According to Zacks, analysts expect that Esperion Therapeutics will report full-year earnings of ($4.03) per share for the current fiscal year, with EPS estimates ranging from ($4.25) to ($3.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($6.35) per share, with EPS estimates ranging from ($10.05) to ($3.55). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.42). The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $0.99 million. During the same period in the prior year, the firm earned ($1.86) earnings per share.

ESPR has been the topic of a number of analyst reports. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, August 29th. Goldman Sachs Group raised Esperion Therapeutics from a “sell” rating to a “neutral” rating and decreased their price target for the stock from $55.00 to $45.00 in a research note on Monday, September 16th. Stifel Nicolaus dropped their price objective on Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. ValuEngine raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cowen reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Esperion Therapeutics presently has an average rating of “Buy” and an average price target of $70.44.

In other news, major shareholder Target N. V. Biotech acquired 80,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average price of $33.78 per share, with a total value of $2,702,400.00. Following the transaction, the insider now directly owns 3,652,964 shares in the company, valued at $123,397,123.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Timothy M. Mayleben acquired 2,500 shares of Esperion Therapeutics stock in a transaction that occurred on Friday, September 6th. The shares were purchased at an average price of $35.25 per share, with a total value of $88,125.00. Following the purchase, the chief executive officer now owns 76,015 shares in the company, valued at $2,679,528.75. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 167,500 shares of company stock worth $5,943,925. Insiders own 7.70% of the company’s stock.

A number of large investors have recently made changes to their positions in ESPR. Vanguard Group Inc. grew its stake in shares of Esperion Therapeutics by 27.9% during the second quarter. Vanguard Group Inc. now owns 2,247,286 shares of the biopharmaceutical company’s stock worth $104,543,000 after acquiring an additional 489,863 shares during the last quarter. BlackRock Inc. boosted its stake in Esperion Therapeutics by 6.8% in the 2nd quarter. BlackRock Inc. now owns 1,983,420 shares of the biopharmaceutical company’s stock worth $92,270,000 after purchasing an additional 125,747 shares in the last quarter. Rhenman & Partners Asset Management AB grew its position in Esperion Therapeutics by 59.2% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 655,854 shares of the biopharmaceutical company’s stock worth $24,044,000 after purchasing an additional 243,761 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in Esperion Therapeutics during the 2nd quarter worth approximately $17,898,000. Finally, Northern Trust Corp increased its stake in Esperion Therapeutics by 0.9% during the 2nd quarter. Northern Trust Corp now owns 292,722 shares of the biopharmaceutical company’s stock valued at $13,617,000 after purchasing an additional 2,689 shares in the last quarter.

NASDAQ ESPR traded down $0.87 during trading on Friday, hitting $44.78. The stock had a trading volume of 31,055 shares, compared to its average volume of 361,291. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.41 and a current ratio of 4.41. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.94 and a beta of 1.86. Esperion Therapeutics has a one year low of $33.13 and a one year high of $58.50. The stock has a 50 day simple moving average of $39.26 and a 200 day simple moving average of $42.46.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: Convertible Shares

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.